Viva Biotech Holdings announced that it repurchased 100,000 ordinary shares on 16 June 2026 via on-market transactions at HK$1.18 per share, for a total consideration of HK$0.12 million.

Including this latest trade, Viva Biotech has bought back 28.69 million shares since the current mandate was approved on 12 June 2025, equivalent to 1.35% of the company’s issued share capital on the mandate date. The authorisation permits repurchases of up to 212.84 million shares; thus, 13.49% of the mandate has been utilised to date.

All repurchased shares have yet to be cancelled. As a result, the company’s issued share capital remains unchanged at 2.13 billion shares as of 16 June 2026.

The series of buy-backs executed between 8 May and 16 June 2026 were completed at prices ranging from HK$1.14 to HK$1.57 per share, with volumes spanning from 200,500 to 4.16 million shares per day.

Under Hong Kong Stock Exchange rules, Viva Biotech is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares following the 16 June transaction, extending up to 16 July 2026.